Skip to main content
Premium Trial:

Request an Annual Quote

Ann Hagan, Axel Ullrich, Don Van Dyke

Premium

Ann Hagan has been appointed associate director for extramural activities at the US National Institute of General Medical Sciences. Hagan has been at NIGMS since 2000, and has served as acting associate director since November 2003. Between 1989 and 2000, she was at the National Institute for Diabetes and Digestive and Kidney Diseases, and served as chief of the review branch. Between 1987 and 1989, she was a health scientist administrator in the grants review branch of the NCI. Before joining the NIH she was an assistant professor of biology at American University. She also held a staff fellowship in 1979 at the National Institute of Mental Health, and served as an assistant professor of biology at George Williams College in Downers Grove, Ill. Hagan received BS and MS degrees in biology education and a PhD in physiology, all from the University of Illinois at Urbana-Champaign.

Axel Ullrich, director of the department of molecular biology at the Max Planck Institute of Biochemistry in Martinsried, Germany has been named to lead the Singapore Onco Genome Laboratory beginning in June 2004. Ullrich will be joined by four postdoctoral researchers from Max Planck, including Sylvia Streit, Jens Ruhe, Stefan Hart, and Katja Specht, as well as researchers from the Genome Institute of Singapore and Singapore’s Institute of Molecular and Cell Biology. The Onco Genome Laboratory is a joint research program between the Max Planck Society and the Agency for Science, Technology and Research. Ullrich co-founded Sugen, a company that develops small molecule drugs to target signal transduction pathways, in 1991. He subsequently founded Axxima Pharmaceuticals in 1998, and U3 Pharma in 2002.

Don Van Dyke has been appointed vice president of business development at Incogen. Van Dyke most recently served as a consultant to Incogen, and prior to that, was VP of sales and marketing at Molecular Mining from 2000 to 2003. Prior to this, he was president and CEO of Bio Image, which produced the first physical map of the human genome.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.